PM2.5 and O3 co-exposure affecting serum LDL-C: evidence from epidemiology and animal models
Yi Zhang , Jiayu Xu , Jiaqi Shi , Ying Ma , Nairui Yu , Xinyan Zhou , Xiaojin Li , Tiancheng Wang , Guang Jia , Zhangjian Chen
Journal of Environmental Exposure Assessment ›› 2025, Vol. 4 ›› Issue (3) : 22
PM2.5 and O3 co-exposure affecting serum LDL-C: evidence from epidemiology and animal models
Air pollution and high low-density lipoprotein cholesterol (LDL-C) levels are both among the top ten global risk factors. This study aims to investigate the impact of long-term exposure to ambient PM2.5 and O3 on LDL-C concentrations in peripheral blood and their effects on hepatic metabolism of LDL-C, based on epidemiological research and animal experiments. Epidemiological research employed a cross-sectional design, enrolling 27,642 male health examinees aged 20-50 in Beijing from March 2021 to February 2023, with an exposure period of one year. Generalized additive models were employed to explore the association between exposure to PM2.5 and O3 and levels of LDL-C. The animal experiment involved rats exposed to an atmosphere containing PM2.5 and O3, alongside a control group breathing air devoid of PM2.5 and O3, with an exposure duration of 15 months. Reverse transcription quantitative polymerase chain reaction and immunohistochemical staining were utilized to detect differences in mRNA expression and protein expression at key loci of LDL-C metabolism between the two groups. In our results, the epidemiological research showed that long-term exposure to PM2.5 was primarily associated with increased levels of LDL-C and elevated risk of LDL-C abnormality. The animal experiments demonstrated that long-term exposure to air pollution suppressed the liver's ability to absorb LDL-C and inhibited the expression of GRP78, which may be one of the mechanisms leading to increased serum LDL-C levels.
Air pollution, PM2.5, ozone / co-exposure, low-density lipoprotein cholesterol, low-density lipoprotein receptor
| [1] |
|
| [2] |
2021 Risk Factors Collaborators. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the global burden of disease study 2021.Lancet2024;403:2162-203 PMCID:PMC11120204 |
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
de Sluis B, Wijers M, Herz J. News on the molecular regulation and function of hepatic low-density lipoprotein receptor and LDLR-related protein 1.Curr Opin Lipidol2017;28:241-7 PMCID:PMC5482905 |
| [39] |
|
| [40] |
|
| [41] |
|
| [42] |
|
| [43] |
|
| [44] |
|
| [45] |
|
| [46] |
|
| [47] |
|
| [48] |
|
| [49] |
|
| [50] |
|
| [51] |
|
| [52] |
|
| [53] |
|
/
| 〈 |
|
〉 |